ArkBio Announces FDA Clearance to Initiate Phase II Trial of AK0406 for Influenza Prevention

Trial StartAK0406Positive

AI Analysis

Summary

ArkBio announced that the FDA cleared its IND application for AK0406, a long-acting antiviral drug-Fc conjugate, enabling a Phase II trial for influenza prevention. The company is based in Shanghai.

Clinical Trial Data

Phase

Phase 2

Outcome Details

FDA cleared the IND application for AK0406, a long-acting antiviral drug-Fc conjugate (AFC), enabling initiation of a Phase II trial for influenza prevention.

Importance:5/10

Sentiment:

0.40

IND clearancePhase 2influenzaantiviraldrug-Fc conjugatelong-actingChina biotechFDA

Read the original article

Published by PR Newswire Pharma on October 13, 2026 1:00 AM

Read Original